These press releases are intended for business journalists and analysts/investors
GSK’s respiratory medicine Breo Ellipta (fluticasone furoate/vilanterol trifenatate 100/25mcg and 200/25mcg) continues to be available to appropriate patients with asthma and COPD on the PBS.
Read more - Access to Breo Ellipta for respiratory patients on the PBS is unchanged Read more
Read more - GSK transfers Ultiva to Aspen in Australia Read more
Read more - Bexsero (meningococcal B) vaccine availability Read more
Read more - Collaboration and mentorship prove winning formula for manufacturing Read more
Read more - GSK welcomes Medicines Australia strategic agreement Read more
Read more - GSK Australia Reports 2016 results to ASIC Read more
GSK has the utmost sympathy for the people who have been, and are, afflicted by arachnoiditis. It can be a very debilitating and painful condition.
Arachnoiditis has a range of possible causes such as spinal injury, surgery and infection. However, it is difficult to determine the causality of arachnoiditis.
Read more - Statement on arachnoiditis and myelograms Read more
Read more - Availability of Menveo (meningococcal ACWY vaccine) Read more